FR-BT-0005

Gene-Edited Porcine Kidneys — Durable Human Renal Replacement

Gene-edited porcine kidneys can provide sustained, life-supporting renal replacement in living human recipients with a clinically acceptable burden of rejection, infection and immunosuppression.

EscalatingVS-03·since 2026-08-21

Verification Matrix

Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.

VS-01

Assertion

—

VS-02

Published evidence

—

VS-03

Audit

Current from 2026-08-21 — present

VS-04

Replication

—

VS-05

Operation

—

Stage first recorded Current verification position Not yet recorded

State Warrant

Current stateEscalatingVS-03

Why this state?Admission evidence basis includes living-recipient clinical reports and contemporary clinical review; Ribas et al., Nature Medicine 32 (2026), 'Immune profiling in a living human recipient of a gene-edited pig kidney'; ClinicalTrials.gov NCT06878560 (EXPAND); United Therapeutics EXPAND trial disclosures; and FDA xenotransplantation guidance on infectious-risk surveillance. The record is deliberately scoped to durable renal replacement in living humans rather than xenotransplantation generally.

Assessment summaryThe claim enters the corpus under strong two-sided pressure. Living-human xenokidney recipients have demonstrated life-sustaining renal function for weeks and, in a later case, for 271 days, moving the field beyond decedent compatibility and short-lived physiological demonstration. At the same time, acute rejection, persistent innate immune activation, eventual graft dysfunction, proteinuria and the continuing need for intensive immunosuppression and zoonotic surveillance remain material constraints. The EXPAND prospective multicentre study now provides a formal replication pathway with 24-week graft, patient and renal-function endpoints. The Pressure State is ESCALATING because both capability evidence and failure-mechanism evidence are strengthening. Verification Stage is VS-03 because the claim has progressed beyond publication into living-human clinical audit that has exposed real rejection and physiological failure modes, but prospective multi-recipient replication has not yet been established.

In this state since2026-08-21

Evidence Brief · Prototype

A short reading of this record

Derived from the record’s current assessment, evidence trail, attractors and open questions. It adds no new assessment; the State Warrant remains authoritative.

Current position

ESCALATING · VS-03

The claim enters the corpus under strong two-sided pressure. Living-human xenokidney recipients have demonstrated life-sustaining renal function for weeks and, in a later case, for 271 days, moving the field beyond decedent compatibility and short-lived physiological demonstration. At the same time, acute rejection, persistent innate immune activation, eventual graft dysfunction, proteinuria and the continuing need for intensive immunosuppression and zoonotic surveillance remain material constraints. The EXPAND prospective multicentre study now provides a formal replication pathway with 24-week graft, patient and renal-function endpoints. The Pressure State is ESCALATING because both capability evidence and failure-mechanism evidence are strengthening. Verification Stage is VS-03 because the claim has progressed beyond publication into living-human clinical audit that has exposed real rejection and physiological failure modes, but prospective multi-recipient replication has not yet been established.

Evidence trail

7 logged evidence entries inform this record. The complete trail, sources and limits remain below.

What could change it

AT-001 Multigene donor engineering combined with targeted costimulation and complement control. Current programmes converge on removing major xenoantigens, adding human protective transgenes and using targeted immunosuppression. If prospective trials reproduce months-long function while reducing rejection and infection burden, this combination could convert xenokidneys from experimental rescue procedures into a scalable renal-replacement pathway.

Questions retained

OQ-001 What duration and level of dialysis independence should constitute clinically meaningful durable renal replacement for this record?

OQ-002 Can persistent innate xenogeneic activation be sufficiently controlled without making the immunosuppressive burden clinically unacceptable?

OQ-003 Which long-term graft failures arise primarily from immune rejection and which arise from intrinsic cross-species renal physiology?

OQ-004 Do materially different donor-gene architectures converge on comparable human outcomes, or will durable xenokidney viability remain platform-dependent?

OQ-005 What prospective sample size and multicentre consistency should be required before the claim advances from VS-03 Audit to VS-04 Replication?

Mechanisms

Causal mechanisms recorded for this claim. The State Warrant above remains the authoritative current assessment.

BottleneckBN-001

Multilayer xenogeneic immune control. Avoiding hyperacute rejection is insufficient; T-cell, antibody, complement, natural-killer-cell and monocyte/macrophage responses can still injure the graft. Durable clinical use requires these responses to be controlled without an immunosuppressive burden that negates the benefit of transplantation.

Resistance MechanismRM-001

Persistent innate immune activation. Human immune profiling shows that adaptive rejection can be suppressed while monocyte and macrophage activation persists. This creates a plausible route to chronic inflammatory, vascular or fibrotic graft injury after an apparently successful treatment of acute rejection.

Resistance MechanismRM-002

Cross-species renal physiology. Protein handling, haemodynamic regulation, complement and coagulation interactions, endocrine signalling and organ-growth biology differ between pigs and humans. These differences can produce progressive dysfunction even when immediate rejection is prevented.

BottleneckBN-002

Clinical reproducibility. Compassionate-use and individual living-recipient successes establish possibility but not a therapeutic modality. The claim requires prospectively repeated graft survival and renal function across multiple recipients, centres and donor-engineering strategies.

AttractorAT-001

Multigene donor engineering combined with targeted costimulation and complement control. Current programmes converge on removing major xenoantigens, adding human protective transgenes and using targeted immunosuppression. If prospective trials reproduce months-long function while reducing rejection and infection burden, this combination could convert xenokidneys from experimental rescue procedures into a scalable renal-replacement pathway.

Assessment History

2026-08-21

Initial assessment — Escalating

Admission evidence basis includes living-recipient clinical reports and contemporary clinical review; Ribas et al., Nature Medicine 32 (2026), 'Immune profiling in a living human recipient of a gene-edited pig kidney'; ClinicalTrials.gov NCT06878560 (EXPAND); United Therapeutics EXPAND trial disclosures; and FDA xenotransplantation guidance on infectious-risk surveillance. The record is deliberately scoped to durable renal replacement in living humans rather than xenotransplantation generally.

Claim Lineage

Historical narrative recorded for this claim. It does not override the current State Warrant.

1990s–2010s

Kidney xenotransplantation remains primarily a preclinical feasibility programme. Hyperacute rejection, cross-species immune incompatibility and infectious risk dominate the claim.

2022–23

Gene-edited porcine kidneys are transplanted into brain-dead human decedents. Human physiological function and avoidance of immediate hyperacute rejection become directly observable, but living-human durability remains untested.

2024

The first living human receives a heavily gene-edited pig kidney. The graft provides life-sustaining renal function; an acute T-cell rejection episode is reversed. The frontier moves from basic compatibility to immune control and durability.

2025–26

Living-recipient experience extends graft function into months, including a 271-day case, while immune profiling identifies persistent innate activation and other clinical reports expose proteinuria, antibody-mediated injury, graft dysfunction and infection pressures. The first prospective multicentre clinical trial begins.

2026 onward

The decisive question becomes reproducibility: whether 24-week and longer graft survival, renal function and acceptable safety can be demonstrated across multiple living recipients and centres rather than isolated experimental cases.

Open Questions

Questions retained in this record. The current State Warrant may have narrowed or reframed earlier questions.

OQ-001

What duration and level of dialysis independence should constitute clinically meaningful durable renal replacement for this record?

Raised 2026-08-21

OQ-002

Can persistent innate xenogeneic activation be sufficiently controlled without making the immunosuppressive burden clinically unacceptable?

Raised 2026-08-21

OQ-003

Which long-term graft failures arise primarily from immune rejection and which arise from intrinsic cross-species renal physiology?

Raised 2026-08-21

OQ-004

Do materially different donor-gene architectures converge on comparable human outcomes, or will durable xenokidney viability remain platform-dependent?

Raised 2026-08-21

OQ-005

What prospective sample size and multicentre consistency should be required before the claim advances from VS-03 Audit to VS-04 Replication?

Raised 2026-08-21

Mutation Log

Mutation	Date	Field	Prior value	Current value
M-005	2026-08-21	diagnosis_held	—	DIAGNOSIS-HELD
M-004	2026-08-21	mechanisms_recorded	—	MECHANISMS-RECORDED
M-003	2026-08-21	assessment_issued	—	ASSESSMENT-ISSUED
M-002	2026-08-21	instances_logged	—	INSTANCES-LOGGED
M-001	2026-08-21	record_created	—	RECORD-CREATED

Evidence Sources

7 instances on recordShow sources ↓Hide ↑

IN-001Decedent-human xenokidney studies — short-term renal function without hyperacute rejectionsupportive

IN-002First living-recipient gene-edited pig kidney — life-sustaining renal function for 51 dayssupportive

IN-003271-day living-recipient xenokidney — months-long function followed by graft explantationpartial

IN-004Immune profiling — reversible T-cell rejection but persistent innate activationcontesting

IN-005EXPAND trial — first prospective multicentre xenokidney study enters recruitment and dosingpartial

IN-006Clinical review evidence — antibody, complement and physiological barriers remain activecontesting

IN-007FDA xenotransplantation guidance — PERV and zoonotic-risk surveillance remains a standing clinical obligationpartial